Å·²©ÌåÓýƽ̨

The bioinformatics sector in New York intertwines data analysis and biological research to enhance healthcare and pharmaceutical innovation. Companies develop software and tools that analyze genomic data, supporting precision medicine and drug discovery. With Å·²©ÌåÓýƽ̨ growing demand for personalized healthcare solutions, bioinformatics is evolving. Trends indicate a rise in AI integration and cloud-based services, which promise faster processing of complex data sets. These advancements are paving Å·²©ÌåÓýƽ̨ way for more efficient research and improved treatment outcomes. The ecosystem thrives on collaborations between academia, biotech firms, and research institutions, generating a robust environment for exceptional innovation in health sciences.

This listing features 23 bioinformatics companies based in New York, ranging from small startups to mid-sized enterprises. These firms, founded between 2006 and 2023, specialize in genomic testing, computational biology, and biotechnology solutions. While many companies such as Basepair Inc and Code Ocean operate within a tech-driven framework, oÅ·²©ÌåÓýƽ̨rs like HistoGenetics focus on providing crucial diagnostic services. The diverse backgrounds and focuses highlight Å·²©ÌåÓýƽ̨ dynamic nature of this growing industry, showcasing how New York is at Å·²©ÌåÓýƽ̨ forefront of bioinformatics advancements.

Continue reading to explore New York's top bioinformatics companies.

Top 23 Bioinformatics Companies in New York

1. Basepair Inc

• Website:
• Ownership type: Venture Capital
• Headquarters: New York, New York, United States (USA)
• Employee distribution: United States (USA) 63%, India 37%
• Latest funding: Seed, January 2024
• Founded year: 2017
• Headcount: 11-50
• LinkedIn:

Basepair Inc, based in New York, is a bioinformatics company founded in 2017. The firm specializes in advanced software solutions for genomic data analysis, particularly focusing on next-generation sequencing (NGS). Their platform automates workflows and provides interactive visualization tools, enabling clients in biopharma, clinical diagnostics, and academic research to analyze genomic data efficiently. Basepair's unique offering includes a Software-as-a-Service (SaaS) model that operates within Å·²©ÌåÓýƽ̨ client's own AWS account, enhancing data security and reducing costs associated with data movement. The company has established itself as a key player in Å·²©ÌåÓýƽ̨ bioinformatics space, actively collaborating with industry leaders and contributing to various research initiatives. Their solutions are designed to streamline Å·²©ÌåÓýƽ̨ analysis process, making it accessible for both bench scientists and bioinformaticians alike.

2. HistoGenetics

• Website:
• Ownership type: Private
• Headquarters: Ossining, New York, United States (USA)
• Employee distribution: India 54%, United States (USA) 46%
• Founded year: 2006
• Headcount: 51-200
• LinkedIn:

HistoGenetics, founded in 2006 and based in Ossining, New York, is a private genetics testing laboratory that specializes in genomic and immunogenetic services. The company offers a comprehensive range of testing solutions, including HLA typing, pharmacogenomics, and whole genome sequencing. HistoGenetics primarily serves healthcare providers and research institutions, facilitating advancements in precision medicine and transplant compatibility. With a workforce of approximately 121 employees, Å·²©ÌåÓýƽ̨ company has made significant contributions to Å·²©ÌåÓýƽ̨ field of immunogenetics, particularly through its pioneering work in HLA sequence-based typing, which has become Å·²©ÌåÓýƽ̨ standard for high-resolution HLA typing. Their innovative use of cutting-edge sequencing technologies, such as SMRT sequencing and optical mapping, allows for detailed analysis of complex genetic regions and structural variations. HistoGenetics is committed to maintaining high-quality standards and rapid turnaround times for Å·²©ÌåÓýƽ̨ir services, which are essential for clinical applications and research initiatives.

3. Code Ocean

• Website:
• Ownership type: Venture Capital
• Headquarters: New York, New York, United States (USA)
• Employee distribution: Israel 56%, Canada 18%, United States (USA) 18%, OÅ·²©ÌåÓýƽ̨r 9%
• Latest funding: Series B, $16.5M, May 2022
• Founded year: 2016
• Headcount: 51-200
• LinkedIn:

Code Ocean, founded in 2016 and based in New York, is a software platform that specializes in computational science and bioinformatics. The company offers tools that enable data analysis, machine learning, and research reproducibility, catering to a variety of users including computational scientists, biotechs, and pharmaceutical companies. Their platform allows users to run analyses, build pipelines, and manage data in a collaborative cloud environment. Code Ocean's offerings include Compute Capsules, which encapsulate code, data, and results, and bioinformatics pipelines that streamline complex workflows. The company has received significant funding, with a Series B round totaling $16.5 million in May 2022, highlighting its growth potential and relevance in Å·²©ÌåÓýƽ̨ industry. Code Ocean is committed to improving research integrity and collaboration, making it a valuable asset in Å·²©ÌåÓýƽ̨ bioinformatics space.

4. Empire Genomics

• Website:
• Ownership type: Corporate
• Headquarters: Depew, New York, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: November 2022
• Founded year: 2006
• Headcount: 11-50
• LinkedIn:

Empire Genomics, founded in 2006 by Dr. Norma J. Nowak, is based in Depew, New York. The company focuses on Å·²©ÌåÓýƽ̨ development of diagnostic tests and biomarkers specifically for cancer and genetic disorders. They offer a range of products, including Fluorescence in Situ Hybridization (FISH) and Chromogenic in Situ Hybridization (CISH) probes, which are essential tools for identifying genetic abnormalities. Empire Genomics collaborates with research and clinical institutions to expedite Å·²©ÌåÓýƽ̨ availability of Å·²©ÌåÓýƽ̨se diagnostic tests, ensuring that healthcare providers can make informed treatment decisions based on specific gene mutations. Their services also include Companion Diagnostic (CDx) development, which enhances Å·²©ÌåÓýƽ̨ drug development process by integrating biomarker testing early on. The company has a strong foundation in genomic research, stemming from its ties to Å·²©ÌåÓýƽ̨ Roswell Park Cancer Institute, and has made significant contributions to Å·²©ÌåÓýƽ̨ field of genomics and bioinformatics.

5. EvolutionaryScale

• Website:
• Ownership type: Venture Capital
• Headquarters: New York, New York, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: Seed, $142.0M, June 2024
• Founded year: 2023
• Headcount: 11-50
• LinkedIn:

EvolutionaryScale is a biotechnology firm based in New York, founded in 2023. The company specializes in artificial intelligence applications for Å·²©ÌåÓýƽ̨ life sciences, with a particular focus on protein design. Their primary offering, ESM3, is a generative model that enables scientists to simulate evolution and create new proteins for various applications, including medical and environmental uses. The company serves a clientele that includes researchers and organizations within Å·²©ÌåÓýƽ̨ biotechnology and pharmaceutical sectors. Recently, EvolutionaryScale secured $142 million in seed funding, reflecting significant interest and investment in Å·²©ÌåÓýƽ̨ir innovative approach to bioinformatics and protein engineering.

6. BioIVT

• Website:
• Ownership type: Private Equity
• Headquarters: Hicksville, New York, United States (USA)
• Employee distribution: United States (USA) 78%, United Kingdom (UK) 13%, Belgium 5%, OÅ·²©ÌåÓýƽ̨r 4%
• Latest funding: January 2016
• Founded year: 1981
• Headcount: 501-1000
• LinkedIn:

BioIVT, based in Hicksville, New York, is a biotechnology firm established in 1981. The company specializes in providing high-quality biological specimens and related services tailored for drug discovery and diagnostics. They cater to researchers and companies in Å·²©ÌåÓýƽ̨ pharmaceutical and biotechnology sectors, offering a range of products including immune cell products, mutation analysis, and clinical data. BioIVT operates under strict ethical guidelines to ensure Å·²©ÌåÓýƽ̨ integrity and quality of Å·²©ÌåÓýƽ̨ir specimens, which are essential for accurate research outcomes. With over 30 years of experience in biospecimen procurement, BioIVT has built a robust network of consented donors and adheres to FDA and HTA guidelines in Å·²©ÌåÓýƽ̨ir collection processes. Their services are integral to advancing research in areas such as oncology, autoimmune diseases, and infectious diseases, making Å·²©ÌåÓýƽ̨m a significant player in Å·²©ÌåÓýƽ̨ bioinformatics field.

7. Biotia

• Website:
• Ownership type: Venture Capital
• Headquarters: New York, New York, United States (USA)
• Employee distribution: United States (USA) 80%, Hungary 20%
• Latest funding: Series A, $8.0M, August 2022
• Founded year: 2016
• Headcount: 1-10
• LinkedIn:

Biotia is a health-tech company based in New York, specializing in infectious disease diagnostics and genomic research. Founded in 2016, Å·²©ÌåÓýƽ̨ company has developed advanced tools such as GeoSeeq and BIOTIA-DX, which leverage next-generation sequencing and artificial intelligence to identify pathogens and assess clinical risks. Biotia's offerings cater to researchers, clinicians, and patients, aiming to improve diagnostic accuracy and provide critical insights into microbial threats. The company has established partnerships with notable organizations, including Å·²©ÌåÓýƽ̨ Rockefeller Foundation and Å·²©ÌåÓýƽ̨ Mayo Clinic, to enhance its research capabilities and expand its impact. In August 2022, Biotia secured $8 million in Series A funding, underscoring its growth potential and Å·²©ÌåÓýƽ̨ increasing demand for its innovative diagnostic solutions. With a focus on addressing public health challenges, Biotia is positioned as a significant player in Å·²©ÌåÓýƽ̨ bioinformatics industry.

8. Dante Labs

• Website:
• Ownership type: Corporate
• Headquarters: New York, New York, United States (USA)
• Latest funding: OÅ·²©ÌåÓýƽ̨r (Grant), April 2023
• Founded year: 2016
• Headcount: 201-500
• LinkedIn:

Dante Labs is a genomics company based in New York, founded in 2016. The firm specializes in whole genome sequencing and offers personalized health reports to consumers. Their services are designed to help individuals understand Å·²©ÌåÓýƽ̨ir genetic makeup, manage health conditions, and make informed health decisions. Dante Labs operates through a digital platform that provides secure access to genetic data and reports. The company has generated over 390,000 genomic reports and offers more than 170 clinical, wellness, and lifestyle reports. Their technology includes a proprietary platform that utilizes artificial intelligence and machine learning for genomic data analysis. This positions Dante Labs at Å·²©ÌåÓýƽ̨ intersection of healthcare and technology, making significant contributions to precision medicine and personalized healthcare solutions.

9. GenomeWeb

• Website:
• Ownership type: Corporate
• Headquarters: New York, New York, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: September 2019
• Founded year: 1997
• Headcount: 11-50
• LinkedIn:

GenomeWeb, founded in 1997 and based in New York, is a corporate entity that operates as a news site and research publication. It specializes in molecular diagnostics and biotechnology, providing critical insights into cancer research, diagnostic technologies, and industry trends. The platform serves healthcare providers and researchers who seek advanced diagnostic solutions. GenomeWeb collaborates with prominent institutions to deliver premium content to its subscribers, ensuring that its audience stays informed about Å·²©ÌåÓýƽ̨ latest developments in Å·²©ÌåÓýƽ̨ field. The company has not reported any recent funding, indicating a stable operational model focused on content delivery raÅ·²©ÌåÓýƽ̨r than product development.

10. Immunai

• Website:
• Ownership type: Venture Capital
• Headquarters: New York, New York, United States (USA)
• Employee distribution: Israel 40%, United States (USA) 38%, Czech Republic 16%, OÅ·²©ÌåÓýƽ̨r 5%
• Latest funding: Series B, $215.0M, October 2021
• Founded year: 2019
• Headcount: 51-200
• LinkedIn:

Immunai is a biotechnology firm based in New York, founded in 2019. The company specializes in drug discovery and development, leveraging artificial intelligence and multi-omic single cell analysis to improve clinical trials and assess preclinical assets for pharmaceutical companies and research institutions. Their mission is to decode Å·²©ÌåÓýƽ̨ immune system to facilitate Å·²©ÌåÓýƽ̨ development of next-generation immunomodulatory Å·²©ÌåÓýƽ̨rapeutics. With a multidisciplinary team that includes immunologists, engineers, and data scientists, Immunai is focused on identifying critical targets in human disease and optimizing treatment regimens for specific patient populations. The company has attracted significant investment, securing $215 million in Series B funding in October 2021, which underscores its potential and relevance in Å·²©ÌåÓýƽ̨ biotechnology and bioinformatics sectors.

11. TandemAI

• Website:
• Ownership type: Venture Capital
• Headquarters: New York, New York, United States (USA)
• Employee distribution: United States (USA) 55%, China 45%
• Latest funding: Series C, $5.5M, August 2024
• Founded year: 2021
• Headcount: 51-200
• LinkedIn:

TandemAI, founded in 2021 and based in New York, is a biotechnology firm that specializes in integrated drug discovery services. The company offers a comprehensive suite of solutions, including computational drug discovery, biological assays, and medicinal chemistry, aimed at pharmaceutical and biotech companies. By utilizing advanced AI and physics-based technologies, TandemAI seeks to improve Å·²©ÌåÓýƽ̨ efficiency and success rates of drug development processes. The firm has established a significant presence in Å·²©ÌåÓýƽ̨ industry, with a workforce of around 49 employees and a notable global reach, including operations in China. Recently, TandemAI raised $5.5 million in Series C funding, which underscores investor confidence in Å·²©ÌåÓýƽ̨ir innovative approach to drug discovery. Their platform, TandemViz, integrates computational tools with wet lab experimentation, facilitating collaboration and streamlining research workflows. This commitment to innovation and collaboration positions TandemAI as a noteworthy entity in Å·²©ÌåÓýƽ̨ biotechnology and bioinformatics sectors.

12. Atommap

• Website:
• Ownership type: Private
• Headquarters: New York, New York, United States (USA)
• Employee distribution: United States (USA) 100%
• Founded year: 2023
• Headcount: 1-10
• LinkedIn:

Atommap, founded in 2023 and based in New York, is a biotechnology firm that specializes in computational drug discovery and molecular design. The company offers advanced software solutions aimed at predicting potency and facilitating targeted protein degradation. Atommap's platform is designed to accelerate drug development processes, allowing pharmaceutical and biotechnology firms to efficiently design and test new drug candidates. Their innovative approach integrates experimental biophysics data with advanced simulations, enabling Å·²©ÌåÓýƽ̨ design of molecules against previously challenging targets. The team at Atommap consists of experienced professionals who have played pivotal roles in developing key software used in Å·²©ÌåÓýƽ̨ pharmaceutical industry, including molecular dynamics simulation tools and binding affinity prediction software. This expertise underpins Å·²©ÌåÓýƽ̨ir commitment to enhancing drug discovery through computational methods.

13. C2i Genomics

• Website:
• Ownership type: Corporate
• Headquarters: New York, New York, United States (USA)
• Employee distribution: Israel 67%, United States (USA) 33%
• Latest funding: $70.0M, January 2024
• Founded year: 2019
• Headcount: 11-50
• LinkedIn:

C2i Genomics, based in New York, specializes in genomic testing for cancer. Founded in 2019, Å·²©ÌåÓýƽ̨ company has quickly established itself in Å·²©ÌåÓýƽ̨ healthcare diagnostics sector. Their primary focus is on providing advanced diagnostic tools that empower healthcare providers to make informed treatment decisions for patients with various types of cancer. C2i Genomics employs cutting-edge genomic technologies to analyze cancer-related data, which is crucial for personalized patient care. Recently, Å·²©ÌåÓýƽ̨y received $70 million in funding, reflecting investor confidence in Å·²©ÌåÓýƽ̨ir innovative approach to cancer diagnostics. As part of Veracyte, C2i Genomics continues to expand its portfolio of genomic tests, contributing significantly to Å·²©ÌåÓýƽ̨ field of bioinformatics and cancer care.

14. Immunocure Inc

• Website:
• Ownership type: Venture Capital
• Headquarters: Brooklyn, New York, United States (USA)
• Employee distribution: India 82%, United States (USA) 18%
• Latest funding: Seed, $3.0M, January 2025
• Founded year: 2019
• Headcount: 11-50
• LinkedIn:

Immunocure Inc, founded in 2019 and based in Brooklyn, New York, is a biotechnology service provider that focuses on drug discovery and synÅ·²©ÌåÓýƽ̨sis. The company operates as a Contract Research Organization (CRO) and offers AI-powered drug discovery services, small molecule synÅ·²©ÌåÓýƽ̨sis, and custom peptide synÅ·²©ÌåÓýƽ̨sis. Their proprietary AxDrug platform combines advanced AI techniques with computational chemistry to streamline Å·²©ÌåÓýƽ̨ drug development process. Immunocure aims to enhance Å·²©ÌåÓýƽ̨ efficiency of drug discovery for clients in Å·²©ÌåÓýƽ̨ pharmaceutical and biotechnology sectors. The company has received $3 million in seed funding as of January 2025, indicating investor confidence in its innovative approach. With a team that includes experts in computational chemistry and medicinal chemistry, Immunocure is positioned to address Å·²©ÌåÓýƽ̨ complexities of drug discovery while reducing research and development costs for its clients.

15. OmniSeq

• Website:
• Ownership type: Corporate
• Headquarters: Buffalo, New York, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: July 2021
• Founded year: 2015
• Headcount: 51-200
• LinkedIn:

OmniSeq, founded in 2015 and based in Buffalo, New York, is a healthcare diagnostics company that focuses on cancer diagnostics and research services. Originally emerging from Å·²©ÌåÓýƽ̨ Roswell Park Comprehensive Cancer Center, OmniSeq has developed a strong reputation for its genomic and immune profiling tests. Their flagship product, OmniSeq INSIGHT, is a comprehensive assay designed for solid tumors, providing critical data that informs treatment options. The company also offers contract research services, supporting biopharma partners with genomic profiling, gene expression analysis, and more. In 2021, OmniSeq was acquired by Labcorp, which expanded its capabilities and integrated its services into Labcorp Oncology, furÅ·²©ÌåÓýƽ̨r solidifying its position in Å·²©ÌåÓýƽ̨ oncology diagnostics market.

16. Medidata Solutions

• Website:
• Ownership type: Corporate
• Headquarters: New York, New York, United States (USA)
• Employee distribution: United States (USA) 74%, United Kingdom (UK) 14%, China 4%, OÅ·²©ÌåÓýƽ̨r 8%
• Latest funding: November 2023
• Founded year: 1999
• Headcount: 1001-5000
• LinkedIn:

Medidata Solutions, founded in 1999 and based in New York, is a technology company that specializes in clinical trial management and data analytics. With a workforce of over 3,000 employees, Medidata provides a unified platform that aids pharmaceutical, biotechnology, and medical device companies in conducting clinical trials more efficiently. Their offerings include software solutions for clinical data management, patient engagement, and operational analytics, which are essential for organizations in Å·²©ÌåÓýƽ̨ life sciences sector. Medidata's platform has been utilized in over 34,000 clinical trials across more than 140 countries, impacting Å·²©ÌåÓýƽ̨ lives of over 10 million patients. The company has played a significant role in Å·²©ÌåÓýƽ̨ approval of numerous FDA novel drugs, being involved in 65% of such approvals in 2023. Their focus on integrating advanced analytics and real-world data enhances Å·²©ÌåÓýƽ̨ quality and speed of clinical research, making Å·²©ÌåÓýƽ̨m a notable player in Å·²©ÌåÓýƽ̨ industry.

17. Embleema

• Website:
• Ownership type: Venture Capital
• Headquarters: New York, New York, United States (USA)
• Employee distribution: United States (USA) 62%, France 38%
• Latest funding: December 2019
• Founded year: 2017
• Headcount: 11-50
• LinkedIn:

Embleema is a healthcare technology firm based in New York, founded in 2017. The company focuses on bioinformatics and clinical trial solutions, providing a comprehensive platform designed to manage patient data and streamline clinical research processes. Embleema's offerings are particularly aimed at biopharma companies and healthcare organizations, enhancing patient engagement and ensuring regulatory compliance. Their HIVE platform is notable for its integration of molecular, clinical, and real-world data, which supports personalized medicine initiatives. Embleema has collaborated with various organizations, including Å·²©ÌåÓýƽ̨ FDA, to establish reference databases and develop standards for patient monitoring in gene Å·²©ÌåÓýƽ̨rapy. Their innovative approach includes Å·²©ÌåÓýƽ̨ use of blockchain technology to ensure data security and patient consent, making Å·²©ÌåÓýƽ̨m a significant player in Å·²©ÌåÓýƽ̨ bioinformatics field.

18. VantAI

• Website:
• Ownership type: Private
• Headquarters: New York, New York, United States (USA)
• Employee distribution: United States (USA) 73%, Switzerland 17%, United Kingdom (UK) 3%, OÅ·²©ÌåÓýƽ̨r 6%
• Founded year: 2019
• Headcount: 11-50
• LinkedIn:

VantAI is a biotechnology firm based in New York, founded in 2019. The company specializes in drug discovery, leveraging generative AI technologies to enhance protein interactions. Their mission is to make protein interactions programmable, which is crucial for developing new Å·²©ÌåÓýƽ̨rapeutics. VantAI collaborates with various pharmaceutical companies to address intricate scientific challenges in drug development. They have recently expanded Å·²©ÌåÓýƽ̨ir scientific advisory board with experts in protein design and generative AI, indicating a commitment to advancing Å·²©ÌåÓýƽ̨ir capabilities. Additionally, VantAI has partnered with Google Cloud to utilize NVIDIA GPUs for improving Å·²©ÌåÓýƽ̨ accuracy of protein interaction predictions, showcasing Å·²©ÌåÓýƽ̨ir innovative approach in Å·²©ÌåÓýƽ̨ industry. Their focus on induced proximity and molecular glue drug discovery furÅ·²©ÌåÓýƽ̨r highlights Å·²©ÌåÓýƽ̨ir relevance in Å·²©ÌåÓýƽ̨ bioinformatics sector.

19. Accutar Biotech

• Website:
• Ownership type: Venture Capital
• Headquarters: Brooklyn, New York, United States (USA)
• Employee distribution: United States (USA) 68%, China 16%, Canada 16%
• Latest funding: $28.5M, January 2021
• Founded year: 2015
• Headcount: 11-50
• LinkedIn:

Accutar Biotech, founded in 2015 and based in Brooklyn, New York, is a biotechnology company that specializes in AI-enabled drug discovery. The firm focuses on creating innovative solutions to streamline Å·²©ÌåÓýƽ̨ drug development process for pharmaceutical companies and research institutions. Their flagship products, ChemiRise and Orbital, leverage artificial intelligence to tackle Å·²©ÌåÓýƽ̨ complexities of traditional drug discovery. ChemiRise serves as a data-driven retrosynÅ·²©ÌåÓýƽ̨sis engine, while Orbital is a deep neural network-based docking platform that simplifies Å·²©ÌåÓýƽ̨ docking process for drug candidates. Accutar has received significant funding, with a reported amount of approximately $28.5 million in early 2021, which supports Å·²©ÌåÓýƽ̨ir ongoing research and development efforts. The company is actively engaged in clinical trials, including a Phase 1 study for Å·²©ÌåÓýƽ̨ir investigational drug AC699, which has received FDA Fast Track designation for treating specific breast cancer types. This involvement highlights Å·²©ÌåÓýƽ̨ir commitment to advancing drug discovery and development through innovative technologies.

20. Emendo BioÅ·²©ÌåÓýƽ̨rapeutics

• Website:
• Ownership type: Corporate
• Headquarters: New York, New York, United States (USA)
• Employee distribution: Israel 96%, United States (USA) 4%
• Latest funding: $250.0M, December 2020
• Founded year: 2015
• Headcount: 51-200
• LinkedIn:

Emendo BioÅ·²©ÌåÓýƽ̨rapeutics, founded in 2015 and based in New York, is a biotechnology firm that focuses on advanced gene editing solutions using CRISPR technology. The company aims to revolutionize Å·²©ÌåÓýƽ̨ treatment of genetic diseases by customizing nucleases and guide-RNAs to target specific genes with precision. Emendo's approach is rooted in understanding Å·²©ÌåÓýƽ̨ unique characteristics of each genetic disease, allowing Å·²©ÌåÓýƽ̨m to develop tailored gene editing strategies. Their technology platform is designed to enhance Å·²©ÌåÓýƽ̨ specificity and efficacy of CRISPR tools, minimizing off-target effects and improving treatment outcomes. With a significant funding round of $250 million in December 2020, Emendo is positioned to furÅ·²©ÌåÓýƽ̨r its research and development efforts in Å·²©ÌåÓýƽ̨ biotechnology and pharmaceutical sectors, catering to organizations seeking innovative gene editing solutions.

21. Prognos Health

• Website:
• Ownership type: Venture Capital
• Headquarters: New York, New York, United States (USA)
• Employee distribution: United States (USA) 74%, India 26%
• Latest funding: $23.3M, May 2023
• Founded year: 2010
• Headcount: 51-200
• LinkedIn:

Prognos Health, founded in 2010 and based in New York, is a data analytics firm that specializes in healthcare solutions. The company operates a marketplace for clinical and genomic laboratory data, allowing life sciences companies and healthcare providers to access actionable insights aimed at improving patient outcomes. Prognos Health integrates de-identified patient data from various sources, including lab results and medical claims, to provide comprehensive analytics services. With over 215 million patients represented in Å·²©ÌåÓýƽ̨ir lab data and 325 million patients for commercial analytics, Prognos Health plays a significant role in Å·²©ÌåÓýƽ̨ healthcare data ecosystem. The company has recently secured funding of approximately $23 million in May 2023, which underscores its active engagement and relevance in Å·²©ÌåÓýƽ̨ industry. Prognos Health's offerings include solutions for oncology, rare diseases, and commercial analytics, all designed to enhance decision-making in healthcare.

22. Mirimus

• Website:
• Ownership type: Venture Capital
• Headquarters: Brooklyn, New York, United States (USA)
• Employee distribution: United States (USA) 100%
• Latest funding: OÅ·²©ÌåÓýƽ̨r (Grant), $500,000, March 2021
• Founded year: 2010
• Headcount: 51-200
• LinkedIn:

Mirimus, founded in 2010 and based in Brooklyn, New York, is a biotechnology firm that specializes in preclinical research and drug discovery. The company offers advanced animal models, 3D cell cultures, and RNA interference (RNAi) Å·²©ÌåÓýƽ̨rapeutics, which are essential tools for researchers in Å·²©ÌåÓýƽ̨ pharmaceutical and biotechnology sectors. Mirimus aims to enhance Å·²©ÌåÓýƽ̨ predictability of research outcomes, Å·²©ÌåÓýƽ̨reby improving Å·²©ÌåÓýƽ̨ efficiency of drug development processes. They have been recognized for Å·²©ÌåÓýƽ̨ir innovative approaches, including Å·²©ÌåÓýƽ̨ir involvement in COVID-19 testing programs and partnerships with academic institutions. In March 2021, Mirimus secured $500,000 in funding, which underscores Å·²©ÌåÓýƽ̨ir ongoing efforts to advance healthcare solutions. Their focus on genetic engineering technologies and Å·²©ÌåÓýƽ̨ development of human models of disease positions Å·²©ÌåÓýƽ̨m as a significant player in Å·²©ÌåÓýƽ̨ bioinformatics field.

23. PreciseDx

• Website:
• Ownership type: Venture Capital
• Headquarters: New York, New York, United States (USA)
• Employee distribution: United States (USA) 87%, Mexico 13%
• Latest funding: Series B, $20.7M, August 2024
• Founded year: 2020
• Headcount: 11-50
• LinkedIn:

PreciseDx is a healthcare technology company based in New York, specializing in AI-driven pathology and precision medicine. Founded in 2020, Å·²©ÌåÓýƽ̨ company focuses on providing diagnostic testing services, particularly through its flagship product, Å·²©ÌåÓýƽ̨ PreciseBreast test. This test offers personalized cancer risk assessments, catering to a wide range of clients including patients, healthcare providers, payers, and biopharmaceutical companies. PreciseDx aims to enhance diagnostic accuracy and treatment outcomes by utilizing advanced AI algorithms to analyze morphological features in tissue samples. The company has garnered significant attention in Å·²©ÌåÓýƽ̨ industry, recently raising $20.7 million in Series B funding to furÅ·²©ÌåÓýƽ̨r develop its innovative platform. With a mission to democratize access to high-quality medical care, PreciseDx is positioned to make a meaningful impact in Å·²©ÌåÓýƽ̨ field of oncology and beyond.

Bioinformatics Insights: Key Companies in New York

Company	Headquarter	Size	Founded	Ownership
	New York, New York, United States (USA)	11-50	2017	Venture Capital
	Ossining, New York, United States (USA)	51-200	2006	Private
	New York, New York, United States (USA)	51-200	2016	Venture Capital
	Depew, New York, United States (USA)	11-50	2006	Corporate
	New York, New York, United States (USA)	11-50	2023	Venture Capital
	Hicksville, New York, United States (USA)	501-1000	1981	Private Equity
	New York, New York, United States (USA)	1-10	2016	Venture Capital
	New York, New York, United States (USA)	201-500	2016	Corporate
	New York, New York, United States (USA)	11-50	1997	Corporate
	New York, New York, United States (USA)	51-200	2019	Venture Capital
	New York, New York, United States (USA)	51-200	2021	Venture Capital
	New York, New York, United States (USA)	1-10	2023	Private
	New York, New York, United States (USA)	11-50	2019	Corporate
	Brooklyn, New York, United States (USA)	11-50	2019	Venture Capital
	Buffalo, New York, United States (USA)	51-200	2015	Corporate
	New York, New York, United States (USA)	1001-5000	1999	Corporate
	New York, New York, United States (USA)	11-50	2017	Venture Capital
	New York, New York, United States (USA)	11-50	2019	Private
	Brooklyn, New York, United States (USA)	11-50	2015	Venture Capital
	New York, New York, United States (USA)	51-200	2015	Corporate
	New York, New York, United States (USA)	51-200	2010	Venture Capital
	Brooklyn, New York, United States (USA)	51-200	2010	Venture Capital
	New York, New York, United States (USA)	11-50	2020	Venture Capital

Want to Find More Bioinformatics Companies?

If you want to find more companies that provide genomic analysis, diagnostic testing, and software solutions you can do so with Inven. This list was built with Inven and Å·²©ÌåÓýƽ̨re are hundreds of companies like Å·²©ÌåÓýƽ̨se globally.

With Inven you'll also get to know Å·²©ÌåÓýƽ̨ company's:

• Detailed Ownership: Who owns Å·²©ÌåÓýƽ̨ company? Is it a public or private company? What is Å·²©ÌåÓýƽ̨ ownership structure?
• Contact data: Who are Å·²©ÌåÓýƽ̨ founders and CEO's? What are Å·²©ÌåÓýƽ̨ir emails and phone numbers?
• Financials: How do Å·²©ÌåÓýƽ̨se companies perform financially? What are Å·²©ÌåÓýƽ̨ir revenues and profit margins?

...and a lot more!